-
1801
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Published 2025-01-01“…ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.Methods In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments. …”
Get full text
Article -
1802
Clinicopathological Analysis of 14 Cases of Primary Pulmonary Lymphoepithelial Carcinoma
Published 2024-11-01“…It is currently classified as a distinct subtype within squamous cell carcinomas. This study aims to explore the clinicopathological characteristics of PPLEC and its subtypes, with the objective of enhancing understanding and improving diagnostic accuracy for this disease. …”
Get full text
Article -
1803
Harnessing natural polymers and nanoparticles: Synergistic scaffold design for improved wound healing
Published 2025-03-01“…Skin injuries may be due to acute or chronic trauma, infections, and operations and can cause severe dysfunction or death. Hence, early clinical intervention becomes crucial in managing the problem. …”
Get full text
Article -
1804
A Lipiodol Pickering Emulsion Stabilized by Iron‐Doped Carbon Nanozymes for Liver Transarterial Chemoembolization
Published 2025-02-01“…More importantly, upon entry into tumor cells, ICN catalyze the generation of reactive oxygen species via the Fenton‐like reaction while simultaneously consuming intracellular glutathione, thereby inducing tumor cell death via chemodynamic therapy. …”
Get full text
Article -
1805
Oakland score to identify low-risk patients with lower gastrointestinal bleeding performs well among emergency department patients
Published 2025-02-01“…The Oakland Score composite outcome includes re-bleeding, defined as additional blood transfusion requirements and/or a further decrease in hematocrit (Hct) >/= 20% after 24 h in clinical stability; red blood cell transfusion; therapeutic intervention to control bleeding, including surgery, mesenteric embolization, or endoscopic hemostasis; in-hospital death, all cause; and re-admission with further LGIB within 28 days. …”
Get full text
Article -
1806
Nanostructured lipid carriers co-encapsulating Apigenin and Melatonin: An innovative strategy against cancer
Published 2025-02-01“…Cancer affects 9 million people every year constituting one of the main causes of death. However, current treatments are frequently associated with adverse effects and can exhibit limitations in therapeutic efficacy. …”
Get full text
Article -
1807
Targeting ATAD3A Phosphorylation Mediated by TBK1 Ameliorates Senescence‐Associated Pathologies
Published 2025-01-01“…A blocking peptide, TAT‐PEP, specifically abrogating ATAD3A phosphorylation, results in elevated cell death by preventing doxorubicin‐induced senescence, thus leading to enhanced tumor sensitivity to chemotherapy. …”
Get full text
Article -
1808
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model
Published 2024-12-01“…Treatment with gemcitabine or pirarubicin under hyperthermic conditions caused pronounced structural damage to the organoids and increased cell death compared to that in the normothermically treated group. …”
Get full text
Article -
1809
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients...
Published 2025-02-01“…Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate consisting of a humanized IgG1 monoclonal antibody attached via a plasma-stable cleavable linker to a topoisomerase-I inhibitor payload, has shown efficacy alone or in combination with durvalumab, a selective, high-affinity anti-programmed cell death ligand 1 antibody, in early-phase clinical studies. …”
Get full text
Article -
1810
Analysis of MLKL, RIP1 and RIP3 Immunostaining Markers in Human Liver Tissue from Fatal Yellow Fever Cases: Insights into Necroptosis
Published 2024-12-01“…Necroptosis is a regulated form of cell death implicated in several pathological conditions, including viral infections. …”
Get full text
Article -
1811
Multi-omics integration and immune profiling identify possible causal networks leading to uterine microbiome dysbiosis in dairy cows that develop metritis
Published 2025-01-01“…Immune activation and systemic inflammation were characterized by increased proportion of circulating polymorphonuclear cells (PMN) prepartum, B-cell activation at parturition, interleukin-8 prepartum and at parturition, and interleukin-1β at parturition. …”
Get full text
Article -
1812
Risk factors and machine learning prediction models for intrahepatic cholestasis of pregnancy
Published 2025-01-01“…Abstract Background Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs in the second and third trimesters of pregnancy and is associated with a significant risk of fetal complications, including premature birth and fetal death. In clinical practice, the diagnosis of ICP is predominantly based on the presence of pruritus in pregnant women and elevated serum total bile acid. …”
Get full text
Article -
1813
Wheat Leaf Rust Effector Pt48115 Localized in the Chloroplasts and Suppressed Wheat Immunity
Published 2025-01-01“…The amino acid sequence polymorphism analysis of Pt48115 in seven different leaf rust races showed that it was highly conserved. Pt48115 inhibited cell death induced by Bcl-2-associated X protein (BAX) from mice or infestans 1 (INF1) from <i>Phytophthora infestans</i> in <i>Nicotiana benthamiana</i> and by DC3000 in wheat, and its 145–175 amino acids of the C-terminal are critical for its function. …”
Get full text
Article -
1814
Identification of fatty acid anabolism patterns to predict prognosis and immunotherapy response in gastric cancer
Published 2025-01-01“…Abstract Gastric cancer (GC), one of the most common and heterogeneous malignancies, is the second leading cause of cancer death worldwide and is closely related to dietary habits. …”
Get full text
Article -
1815
Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway
Published 2025-01-01“…Furthermore, disruption of tumor-intrinsic Pgam5 significantly facilitated CD8+ T cells activation and improved anti-programmed cell death protein-1 therapeutic efficacy with macrophages depletion compromising synergistic antitumor immune response.Conclusion Our results shed light on the effect of tumor mitochondria dynamics on TAMs in tumor microenvironment. …”
Get full text
Article -
1816
Prognostic Value of Procalcitonin for Morbidity and Mortality in Patients after Cardiac Surgery
Published 2021-01-01“…The postoperative serum PCT level is significantly correlated with sternum wound infection (p=0.001), packed cells (PC) transfusion (p=0.003), and death (p=0.003). …”
Get full text
Article -
1817
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context
Published 2025-01-01“…Summary: Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. …”
Get full text
Article -
1818
Inhibition of platelet activation alleviates diabetes-associated cognitive dysfunction via attenuating blood-brain barrier injury
Published 2025-02-01“…Endothelial cells are the major component of BBB, on which the increased expression of CD40 could mediate BBB dysfunction in diabetics. …”
Get full text
Article -
1819
Type I IFN induces long-chain acyl-CoA synthetase 1 to generate a phosphatidic acid reservoir for lipotoxic saturated fatty acids
Published 2025-01-01“…We propose that ACSL1 induction is a mechanism used by IFN-I to increase phosphatidic acid saturation while protecting the cells from saturated fatty acid-induced cell death.…”
Get full text
Article -
1820
ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer
Published 2023-10-01“…CUT & Tag sequencing and The Cancer Genome Atlas database analysis showed that ERRα participated in glycolysis and programmed cell death, which resulted in EC progression. Conclusions ERRα inhibits pyroptosis in an NLRP3-dependent manner and induces glycolytic metabolism, resulting in cisplatin resistance in EC cells.…”
Get full text
Article